SCHEMBL617875

SCHEMBL617875

N[C@@H](COCCO)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.55
NOS1 P29475 2/20 0.55
NOS2 P35228 2/20 0.55
PTGS1 P23219 1/20 0.41
SLC7A11 Q9UPY5 1/20 0.41
SLC1A1 P43005 4/20 0.40
SLC1A5 Q15758 1/20 0.40
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
SLC7A5 Q01650 2/20 0.38
GSR P00390 2/20 0.38
GRIK1 P39086 2/20 0.38
GRIK2 Q13002 2/20 0.38
GRM1 Q13255 2/20 0.38
GRM2 Q14416 2/20 0.38
SLC1A3 P43003 2/20 0.38
SLC1A2 P43004 2/20 0.38
GRM8 O00222 1/20 0.38
GRM6 O15303 1/20 0.38
GRIN2D O15399 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8093094 1.00 NOS3 (0.55) NOS3NOS1NOS2PTGS1SLC7A11
SCHEMBL6535740 1.00 NOS3 (0.55) NOS3NOS1NOS2PTGS1SLC7A11
SCHEMBL890468 0.96 NOS3 (0.51) NOS3NOS1NOS2PTGS1SLC7A11
SCHEMBL890472 0.96 NOS3 (0.51) NOS3NOS1NOS2PTGS1SLC7A11
SCHEMBL22091990 0.87 NOS3 (0.51) NOS3NOS1NOS2PTGS1SLC7A11
SCHEMBL22091993 0.87 NOS3 (0.51) NOS3NOS1NOS2PTGS1SLC7A11
SCHEMBL31688563 0.84 NOS3 (0.53) NOS3NOS1NOS2PTGS1SLC7A11
SCHEMBL17434420 0.83 NOS3 (0.53) NOS3NOS1NOS2PTGS1SLC7A11
SCHEMBL9423322 0.83 NOS3 (0.53) NOS3NOS1NOS2PTGS1SLC7A11
SCHEMBL8892097 0.83 NOS3 (0.53) NOS3NOS1NOS2PTGS1SLC7A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705050-B2 Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2010-04-27 US claimed
EP-1255726-B1 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS DOMPE PHA R MA SPA RES & MFG (IT) 2009-11-11 EP claimed
CN-100513386-C Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils DOMP S P A (IT) 2009-07-15 CN claimed
US-20080221200-A1 Combination of Organic Compounds ALLISON MALCOLM 2008-09-11 US claimed
EP-1940388-A2 DPP IV INHIBTOR FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND GRAFT REJECTION Novartis AG (CH) 2008-07-09 EP claimed
WO-2007041368-A2 DPP IV INHIBITOR FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND GRAFT REJECTION NOVARTIS AG (CH) 2007-04-12 WO claimed
CN-1479715-A Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils ��ķ�ɷ����޹�˾ 2004-03-03 CN claimed
EP-1086124-B1 NOVEL CYCLOSPORINS CHEM AG C (CH) 2003-11-19 EP claimed
US-6583265-B1 Compound for use in the prevention of viral and bacterial infections C-CHEM AG (CH) 2003-06-24 US claimed
EP-1255726-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.P.A. (IT) 2002-11-13 EP claimed
WO-2001058852-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.p.A. (IT) 2001-08-16 WO claimed
EP-1086124-A1 NOVEL CYCLOSPORINS C-Chem AG (CH) 2001-03-28 EP claimed
WO-1999065933-A1 NOVEL CYCLOSPORINS C-CHEM AG (CH) 1999-12-23 WO claimed
EP-0539319-B1 Pharmaceutical cyclosporin composition NOVARTIS AG (CH) 1999-12-08 EP claimed
EP-0414632-B1 Cyclosporin derivatives SANDOZ LTD (CH) 1996-10-23 EP claimed
US-20250250565-A1 OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES ALPHA ANOMERIC SAS (FR) 2025-08-07 US disclosed
US-20250171500-A1 CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS CALDER BIOSCIENCES INC (US) 2025-05-29 US disclosed
EP-0539319-B1 Pharmaceutical cyclosporin composition NOVARTIS AG (CH) 1999-12-08 EP disclosed
EP-0953630-A1 Transesterification products of corn oil and glycerol and their use in pharmaceutical compositions Novartis AG (CH) 1999-11-03 EP disclosed
WO-1999010374-A1 CYCLOSPORIN A CONJUGATES AND USES THEREFOR WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221200-A1 Combination of Organic Compounds DPP4, DPP3, DPP7 NOS3 414/4885NOS1 773/4885NOS2 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.